Eli Lilly (LLY) Offering Possible 18.48% Return Over the Next 6 Calendar Days

Eli Lilly’s most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $232.50 short put and a strike $227.50 long put offers a potential 18.48% return on risk over the next 6 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $232.50 by expiration. The full premium credit of $0.78 would be kept by the premium seller. The risk of $4.22 would be incurred if the stock dropped below the $227.50 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.

The RSI indicator is at 67.39 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Eli Lilly

Mirikizumab Up-Regulates Genes Associated with Mucosal Healing in Ulcerative Colitis for Up to One Year in Phase 2 Study
Fri, 09 Jul 2021 10:31:00 +0000
Eli Lilly and Company (NYSE: LLY) announced new Phase 2 data showing that gene expression changes induced by mirikizumab in patients with ulcerative colitis (UC) over a 12-week induction treatment were maintained for up to one year. These gene transcript changes, which were unique among those who responded to mirikizumab compared to placebo, were associated with mucosal healing, indicating that mirikizumab affects a distinct molecular healing pathway, compared to the spontaneous healing that occ

Biogen Stock Just Popped For An Odd Reason — Here’s Why
Thu, 08 Jul 2021 20:19:56 +0000
Biogen stock rose Thursday after the Food and Drug Administration signed off on narrower recommendations for Alzheimer’s drug Aduhelm.

SNY vs. LLY: Which Stock Is the Better Value Option?
Thu, 08 Jul 2021 15:40:03 +0000
SNY vs. LLY: Which Stock Is the Better Value Option?

Eli Lilly, Verge Genomics Ink $720M Pact For Amyotrophic Lateral Sclerosis Therapies
Thu, 08 Jul 2021 13:13:56 +0000
Verge Genomics has announced a three-year collaboration with Eli Lilly And Co (NYSE: LLY) to research and develop novel therapies to treat amyotrophic lateral sclerosis (ALS), a motor neuron disease. Under the terms of the three-year agreement, Verge will receive up to $25 million in upfront equity investment and potential near-term payments, with an additional milestone value of $694 million and potential downstream royalties. Verge will apply its all-in-human platform to discover and validate

Lilly’s (LLY) Jardiance Heart Failure Study Meets Main Goal
Wed, 07 Jul 2021 12:39:12 +0000
Lilly’s (LLY) Jardiance significantly reduces the risk of the composite of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction.

Be Sociable, Share!

Related Posts